Skip to main content

Table 3 Multivariate analysis of survival-related characteristics in HG-SOCs

From: Nadir CA-125 level as prognosis indicator of high-grade serous ovarian cancer

Variable PFS (OR, 95% CI) OS (OR, 95% CI)
MDACC JICR MDACC JICR
FIGO stage
 I 1.00 (reference) 1.00 (reference) 1.00 (reference) 1.00 (reference)
 II 1.07 (0.35–3.14) 1.22 (0.54–4.19) 1.24 (0.40–3.98) 1.53 (0.63–4.24)
 III 1.83 (1.18–4.29) 3.24 (1.61–8.93) 2.28 (1.14–8.65) 3.56 (2.02–8.27)
 IV 2.26 (1.24–5.25) 4.37 (2.52–11.05) 3.77 (2.08–10.24) 5.13 (2.72–12.27)
Ascites
 No 1.00 (reference) 1.00 (reference) 1.00 (reference) 1.00 (reference)
 Yes 1.40 (1.16–2.03) 1.85 (1.47–2.73) 1.73 (1.26–2.49) 2.01 (1.55–2.47)
Residual tumors
 No 1.00 (reference) 1.00 (reference) 1.00 (reference) 1.00 (reference)
 Yes 8.54 (4.24–16.82) 9.12 (4.50–17.87) 6.24 (3.19–16.39) 7.35 (3.72–14.08)
Neo-chemotherapy
 Yes 1.00 (reference) 1.00 (reference) 1.00 (reference) 1.00 (reference)
 No 1.28 (0.88–2.24) 1.27 (1.19–1.42) 1.26 (0.36–6.22) 1.17 (0.75–1.93)
Chemotherapy, including paclitaxel
 Yes 1.00 (reference) 1.00 (reference) 1.00 (reference) 1.00 (reference)
 No 1.00 (0.61–2.62) 1.07 (0.86–1.40) 1.21 (0.38–4.77) 1.13(0.74–1.86)
CA-125, decreasing kinetics
 ≥1/32 1.00 (reference) 1.00 (reference) 1.00 (reference) 1.00 (reference)
 <1/32 1.06 (0.84–1.83) 1.37 (1.14–1.92) 1.10 (0.56–2.84) 1.02 (0.65–2.85)
Baseline CA-125 1.00 (0.98–1.02) 1.00 (0.98–1.02) 1.00 (0.97–1.03) 1.00 (0.97–1.03)
CA-125 level at relapse 1.00 (0.97–1.04) 1.00 (0.98–1.01) 1.01 (0.98–1.02) 1.01 (0.99–1.02)
Nadir CA-125 1.02 (1.00–1.04) 1.02 (1.00–1.03) 1.03 (1.01–1.06) 1.03 (1.00–1.05)